Clinical Report: Angiosarcoma Among Patients with Soft Tissue Sarcomas
Overview
This study reviews angiosarcoma cases within a cohort of soft tissue sarcoma patients, highlighting its rarity. Among 12 identified cases, the median overall survival was 9.5 months, with a significant proportion presenting with advanced disease.
Background
Angiosarcoma is a rare and aggressive form of vascular sarcoma, accounting for 1-2% of soft tissue sarcomas. Its clinical significance lies in its rapid progression and poor response to treatment.
Data Highlights
Characteristic
Value
Total Cases
12
Median Age
62 years (range 19–88)
Metastatic/Unresectable Disease
9 patients (75.0%)
Median Overall Survival
9.5 months (95% CI, 6.77–12.22)
Median First-Line PFS
4.8 months (95% CI, 4.24–5.42)
Key Findings
Angiosarcoma represented 2.2% of soft tissue sarcoma cases in the cohort.
41.7% of angiosarcoma cases were cutaneous, while 58.3% were visceral.
75% of patients presented with metastatic or unresectable disease at diagnosis.
First-line therapy was paclitaxel-based in 66.7% of advanced cases.
The median follow-up period was 28.5 months, with 7 deaths recorded.
Overall survival and progression-free survival were notably poor despite treatment.
Clinical Implications
Angiosarcoma often presents at an advanced stage, leading to poor survival outcomes.
Conclusion
Angiosarcoma is rare within the cohort but presents significant challenges in treatment and prognosis.
Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody
